Literature DB >> 12836093

Successful (?) therapy of hemolytic-uremic syndrome with factor H abnormality.

Angela Gerber1, Antje H Kirchhoff-Moradpour, Silke Obieglo, Matthias Brandis, Michael Kirschfink, Peter F Zipfel, Judith A Goodship, Lothar B Zimmerhackl.   

Abstract

We report a patient with continuously recurring hemolytic-uremic syndrome due to factor H deficiency. First at the age of 3 months he showed signs of hemolytic anemia, thrombocytopenia and renal insufficiency, often recurring concomitantly with respiratory tract infections, despite weekly to twice weekly plasma substitution (20 ml/kg body weight). Now at the age of 3.5 years glomerular filtration rate is approximately 50 ml/min/1.73 m(2) and psychomotoric development is normal. Since factor H is mainly synthesized in the liver, hepatic transplantation has been proposed as curative treatment. Before justification of liver transplantation as the ultimate treatment for these patients, an international registry should be developed to optimize and standardize therapeutic alternatives.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12836093     DOI: 10.1007/s00467-003-1192-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  12 in total

Review 1.  Targeting complement in therapy.

Authors:  M Kirschfink
Journal:  Immunol Rev       Date:  2001-04       Impact factor: 12.988

Review 2.  Hemolytic uremic syndrome: how do factor H mutants mediate endothelial damage?

Authors:  P F Zipfel
Journal:  Trends Immunol       Date:  2001-07       Impact factor: 16.687

3.  Combined kidney and liver transplantation for familial haemolytic uraemic syndrome.

Authors:  Giuseppe Remuzzi; Piero Ruggenenti; Daniela Codazzi; Marina Noris; Jessica Caprioli; Giuseppe Locatelli; Bruno Gridelli
Journal:  Lancet       Date:  2002-05-11       Impact factor: 79.321

4.  A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine.

Authors:  G J Schwartz; G B Haycock; C M Edelmann; A Spitzer
Journal:  Pediatrics       Date:  1976-08       Impact factor: 7.124

5.  The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20.

Authors:  Jessica Caprioli; Paola Bettinaglio; Peter F Zipfel; Barbara Amadei; Erica Daina; Sara Gamba; Christine Skerka; Nicola Marziliano; Giuseppe Remuzzi; Marina Noris
Journal:  J Am Soc Nephrol       Date:  2001-02       Impact factor: 10.121

6.  Familial hemolytic uremic syndrome associated with complement factor H deficiency.

Authors:  D Landau; H Shalev; G Levy-Finer; A Polonsky; Y Segev; L Katchko
Journal:  J Pediatr       Date:  2001-03       Impact factor: 4.406

7.  Successful plasma therapy in hemolytic uremic syndrome with factor H deficiency.

Authors:  S Nathanson; V Frémeaux-Bacchi; G Deschênes
Journal:  Pediatr Nephrol       Date:  2001-07       Impact factor: 3.714

8.  Familial relapsing haemolytic uraemic syndrome and complement factor H deficiency.

Authors:  P Warwicker; R L Donne; J A Goodship; T H Goodship; A J Howie; D S Kumararatne; R A Thompson; C M Taylor
Journal:  Nephrol Dial Transplant       Date:  1999-05       Impact factor: 5.992

Review 9.  Factor H and disease: a complement regulator affects vital body functions.

Authors:  P F Zipfel; J Hellwage; M A Friese; G Hegasy; S T Jokiranta; S Meri
Journal:  Mol Immunol       Date:  1999 Mar-Apr       Impact factor: 4.407

10.  Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H.

Authors:  M Ohali; H Shalev; M Schlesinger; Y Katz; L Kachko; R Carmi; S Sofer; D Landau
Journal:  Pediatr Nephrol       Date:  1998-10       Impact factor: 3.714

View more
  15 in total

1.  A favorable outcome of hemolytic uremic syndrome with factor H deficiency.

Authors:  Z Birsin Ozçakar; Fatoş Yalçinkaya; Emel Derelli; Banu Acar; Selçuk Yüksel; Ozden Tulunay; Mesiha Ekim
Journal:  Pediatr Nephrol       Date:  2004-05-11       Impact factor: 3.714

2.  Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome.

Authors:  Gema Ariceta; Nesrin Besbas; Sally Johnson; Diana Karpman; Daniel Landau; Christoph Licht; Chantal Loirat; Carmine Pecoraro; C Mark Taylor; Nicole Van de Kar; Johan Vandewalle; Lothar B Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2008-09-18       Impact factor: 3.714

3.  A rare case: childhood-onset C3 glomerulonephritis due to homozygous factor H deficiency.

Authors:  Krisztina Rusai; Vera Zaller; Agnes Szilagyi; Renate Kain; Zoltan Prohaszka; H Terence Cook; Christoph Aufricht; Klaus Arbeiter
Journal:  CEN Case Rep       Date:  2013-03-16

Review 4.  Renal transplantation in HUS patients with disorders of complement regulation.

Authors:  Lothar Bernd Zimmerhackl; Johanna Scheiring; Friederike Prüfer; C Mark Taylor; Chantal Loirat
Journal:  Pediatr Nephrol       Date:  2006-10-21       Impact factor: 3.714

5.  Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders.

Authors:  Stefan Michelfelder; Juliana Parsons; Lennard L Bohlender; Sebastian N W Hoernstein; Holger Niederkrüger; Andreas Busch; Nicola Krieghoff; Jonas Koch; Benjamin Fode; Andreas Schaaf; Thomas Frischmuth; Martin Pohl; Peter F Zipfel; Ralf Reski; Eva L Decker; Karsten Häffner
Journal:  J Am Soc Nephrol       Date:  2016-12-08       Impact factor: 10.121

Review 6.  aHUS caused by complement dysregulation: new therapies on the horizon.

Authors:  Aoife M Waters; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2010-06-18       Impact factor: 3.714

Review 7.  Clinical practice. Today's understanding of the haemolytic uraemic syndrome.

Authors:  Johanna Scheiring; Alejandra Rosales; Lothar Bernd Zimmerhackl
Journal:  Eur J Pediatr       Date:  2009-08-26       Impact factor: 3.183

Review 8.  Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.

Authors:  M Noris; G Remuzzi
Journal:  Clin Exp Immunol       Date:  2007-12-07       Impact factor: 4.330

9.  Challenges in the management of infantile factor H associated hemolytic uremic syndrome.

Authors:  Guido Filler; Seetha Radhakrishnan; Lisa Strain; Andrew Hill; Greg Knoll; Timothy H Goodship
Journal:  Pediatr Nephrol       Date:  2004-06-16       Impact factor: 3.714

10.  The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.

Authors:  Stefan Michelfelder; Friedericke Fischer; Astrid Wäldin; Kim V Hörle; Martin Pohl; Juliana Parsons; Ralf Reski; Eva L Decker; Peter F Zipfel; Christine Skerka; Karsten Häffner
Journal:  J Am Soc Nephrol       Date:  2018-01-15       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.